BioNexus Gene Lab Corp (BGLC) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
10-2 TOWER B, VERTICAL BUSINESS SUITE, KUALA LUMPUR, 59200 |
| State of Incorp. | WY |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2023 MRQ | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 612 | 2,124 | 2,788 | 366 | |||
| Cash and cash equivalents | 612 | 2,124 | 2,788 | 366 | |||
| Receivables | 32 | 2 | 3 | ||||
| Inventory, net of allowances, customer advances and progress billings | 978 | 1,522 | 1,176 | 8 | |||
| Inventory | 978 | 1,522 | 1,176 | 8 | |||
| Asset, held-for-sale, not part of disposal group | |||||||
| Other undisclosed current assets | 4,401 | 3,504 | 4,019 | 506 | |||
| Total current assets: | 6,022 | 7,150 | 7,985 | 883 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 56 | 41 | 63 | 24 | |||
| Property, plant and equipment | 1,512 | 1,634 | 1,786 | 313 | |||
| Deferred costs | 68 | ||||||
| Other undisclosed noncurrent assets | 1,151 | 681 | 282 | 12 | |||
| Total noncurrent assets: | 2,718 | 2,425 | 2,130 | 349 | |||
| TOTAL ASSETS: | 8,740 | 9,574 | 10,115 | 1,231 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 1,861 | 2,012 | 3,171 | ||||
| Accounts payable | 1,861 | 2,012 | 3,171 | ||||
| Debt | 21 | 46 | 32 | ||||
| Other undisclosed current liabilities | 143 | 295 | 157 | 19 | |||
| Total current liabilities: | 2,004 | 2,329 | 3,374 | 52 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 37 | 78 | 57 | ||||
| Finance lease, liability | 25 | 35 | 45 | ||||
| Liabilities, other than long-term debt | 71 | ||||||
| Deferred income tax liabilities | 31 | ||||||
| Operating lease, liability | 40 | 13 | 42 | 12 | |||
| Other undisclosed noncurrent liabilities | 16 | 2 | |||||
| Total noncurrent liabilities: | 71 | 66 | 80 | 57 | |||
| Total liabilities: | 2,075 | 2,395 | 3,453 | 109 | |||
| Equity | |||||||
| Equity, attributable to parent | 6,665 | 7,180 | 6,662 | 1,122 | |||
| Common stock | 10,930 | 10,780 | 10,780 | 6,485 | |||
| Additional paid in capital | (5,012) | (5,012) | (5,012) | (5,012) | |||
| Accumulated other comprehensive income (loss) | (409) | (100) | 134 | (17) | |||
| Retained earnings (accumulated deficit) | 1,156 | 1,512 | 761 | (333) | |||
| Total equity: | 6,665 | 7,180 | 6,662 | 1,122 | |||
| TOTAL LIABILITIES AND EQUITY: | 8,740 | 9,574 | 10,115 | 1,231 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Revenues | 10,929 | 13,363 | 11,390 | 127 | ||
| Other income | 179 | 66 | 887 | 25 | ||
| Cost of revenue | (9,670) | (11,169) | (9,671) | |||
| Other undisclosed gross profit | (71) | |||||
| Gross profit: | 1,259 | 2,194 | 1,720 | 56 | ||
| Operating expenses | (1,729) | (1,204) | (1,333) | 315 | ||
| Other undisclosed operating income (loss) | 179 | 66 | 887 | (647) | ||
| Operating income (loss): | (291) | 1,056 | 1,274 | (276) | ||
| Nonoperating income (expense) | (240) | 114 | 29 | |||
| Investment income, nonoperating | (6) | (37) | ||||
| Gain (loss), foreign currency transaction, before tax | (234) | 151 | ||||
| Other nonoperating income | 29 | |||||
| Interest and debt expense | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (291) | 815 | 1,387 | (246) | ||
| Other undisclosed loss from continuing operations before income taxes | (12) | |||||
| Income (loss) from continuing operations before income taxes: | (304) | 815 | 1,387 | (246) | ||
| Income tax expense (benefit) | 52 | 27 | 1 | (25) | ||
| Income (loss) from continuing operations: | (251) | 842 | 1,389 | (271) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | 842 | 1,389 | (271) | ||
| Other undisclosed net income (loss) | (105) | (91) | (294) | 25 | ||
| Net income (loss): | (356) | 752 | 1,094 | (246) | ||
| Other undisclosed net income attributable to parent | ||||||
| Net income (loss) available to common stockholders, diluted: | (356) | 752 | 1,094 | (246) | ||
Comprehensive Income ($ in thousands)
| 6/30/2023 TTM | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (356) | 752 | 1,094 | (246) | ||
| Comprehensive income (loss): | (356) | 752 | 1,094 | (246) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (309) | (234) | 151 | 10 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (665) | 518 | 1,245 | (237) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.